|Articles|June 15, 2008

Secondary Prevention of Noncardioembolic Ischemic Stroke
Volume 14
Issue 7 Suppl

Secondary Prevention of Noncardioembolic Ischemic Stroke

Download PDF: Secondary Prevention of Noncardioembolic Ischemic Stroke

Articles in this issue

about 18 years ago

Article

Managed Care Considerations

about 18 years ago

Article

Therapeutic Interventions for Prevention of Recurrent Ischemic Stroke

about 18 years ago

Article

Participating Faculty

about 18 years ago

Article

Introduction

about 18 years ago

Article

Stroke and TIA: Epidemiology, Risk Factors, and the Need for Early Intervention

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Secondary Prevention of Noncardioembolic Ischemic Stroke

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Dermatology Practices Absorb Rising Prior Authorization Costs

Clesrovimab Demonstrates Safety Through a Second RSV Season in High-Risk Infants